FT comment:
Hi everyone,
I hope there was no misunderstanding about the content of the email I received (Kyocera) :
“The plan scheduled to start in 2020 but research is delayed.
Drug approval Japan is still expected.
We will contact you again after the clinical trial results at the university hospital.
Best regards!”
What I wanted to say is that the clinical trial project is still ongoing and has not been dropped, contrary to what some may have said about the fact that Tsuji is no longer the director.
That email seems to indicate that the initial clinical trial is currently underway. If that's the case there should be big news this year.
